Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer

Breast Cancer Research and Treatment

Volumn 86, Issue 3, 2004, Pages 249-257

  Morabito, Alessandro ^a   Gattuso, Domenico ^a   Stani, Simonetta Chiara ^a   Fanelli, Massimo ^a   Ferraù, Francesco ^b   De Sio, Livia ^a   Castellana, Maria Angela ^a   Lorusso, Vito ^c   Priolo, Domenico ^b   Vitale, Stefano ^a   Sarmiento, Roberta ^a   Lo Vullo, Salvatore ^c   Mariani, Luigi ^c   Gasparini, Giampietro ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b Italy   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

advanced breast cancer; docetaxel; pegylated liposomal doxorubicin

Indexed keywords

DOCETAXEL; DOXORUBICIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSESTHESIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; LIVER DISEASE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUROPATHY; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECORDING; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIPOSOMES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 4043084834     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000036898.45123.e9     Document Type: Article

References (34)

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzder AU: Long-term follow-up of patients with complete remission following combination chemoterapy for metastatic breast breast cancer. J Clin Oncol 14: 2197-2205, 1996
2. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 6: 959-962, 2003
3. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197-206, 1993
4. Gasparini G, Dal Fior S, Panizzoni GA, Favretto S, Pozza F: Weekly epirubicin versus doxorubicin as second-line therapy in advanced breast cancer: a randomized clinical trial. Am J Clin Oncol 14: 38-44, 1991
5. Huang L (ed): Covalentely attached polymers and glycans to alter the biodistribution of liposomes. J Liposome Res 2: 289-454, 1992
6. Amantea MA, Forrest A, Northfelt DW, Mamelok R: Population pharmacokinetics and pharmacodynamics of pegylated-liposomial doxorubicin in patients with AIDS-related Kaposi sarcoma. Clin Pharmacol Ther 61: 301-311, 1997
7. Vaage J, Barbera-Guillman E, Abra R, Huang A, Working P: Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73: 1478-1484, 1994
8. Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 11: 11-20, 1997
9. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB: Arrest of human lung tumor xenograft growth in SCID mice using doxorubicin encapsulated in sterically stabilised liposomes. Cancer Res 53: 3964-3967, 1993
10. Vaage J, Donovan D, Mayhew E, Uster: Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer 54: 959-964, 1993
11. Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72: 3671-3675, 1993
12. Northfelt DW, Dezube B, Miler B, et al: Randomized comparative trial of doxil versus adriamycin, bleomycin and vincristine in the treatment of severe AIDS-related Kaposi's sarcoma. Blood 86: 382a [abstr], 1995
13. Goebel FD, Goldstein D, Goos M, Jablonwski H, Stewart JS: Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer 73: 989-994, 1996
14. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon M: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785, 1995
15. Ranson MR, Carmichael J, O'Byrne K, Stewarts S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 3185-3191, 1997
16. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Mangard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first line treatment of advanced breast cancer: report of the EORTC. Ann Oncol 7: 165-171, 1996
17. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murrawsky M, Alaki M, Riva A: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999
18. Crown J: A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol (suppl); 26: 5-9, 1999
19. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Anzannet V, et al.: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467, 1994
20. Burstein HJ, Manola J, Younger J, Parker LM, Bunnel CA, Scheib R: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18: 1212-1219, 2000
21. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G: The microtubule affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996
22. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58: 17-38, 1999.
23. Gasparini G and Harris AL: Angiogenesis: pathological, prognostic and growth factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2: 278-289, 2001
24. Misset JL, Dieras V, Gruia G, Bourgeois H, Cvitkovic E, Kalla S, Bozec L, Beuzeboc P, Jans C, Aussel JP, Riva A, Azli N, Pouillart P: Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10: 553-560, 1999
25. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowsky T, Zaluski J, Pinten T, Krzakowski M, Vorobiof, Leonard R, Kennedy J, Azli N, Murawsky M, Riva A, Pouillart P: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter phase III trial. J Clin Oncol 21: 968-975, 2003
26. Caponigro F, Comella P, Budillon A, Bryce J, Avallone A, De Rosa V, Ionna F, Comella G: Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol 11: 339-342, 2000
27. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeck I, Bruning P, de Valeriola D: EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 13: 910-918, 2002
28. Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountizilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P, Markopoullos C: Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 13: 1737-1742, 2002
29. Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC: Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 19: 3117-3125, 2001
30. Nagore E, Insa A and Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (Hand-Foot) syndrome. Am J Clin Dermatol 1: 225-234, 2000
31. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC: Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 18: 2369-2377, 2000
32. Holmes F, Blum JL, Kruger S, Ratnam S, Liu L, Boehm KA, Asmar L, O'Shaughnessy JA: Breast Cancer Res and Treat 82: 537 [abstr], 2003
33. Bischoff J, Hesse S, Stemmler H, Zauner S, Gutschow K: A Phase I study of PEG liposomal doxorubicin (PLD) plus docetaxel (D) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 282 [abstr], 2003.
34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med 344: 783-792, 2001